Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1984 1
1985 2
1986 6
1987 1
1988 2
1989 3
1990 4
1991 6
1992 3
1993 11
1994 6
1995 11
1996 11
1997 12
1998 25
1999 16
2000 18
2001 19
2002 16
2003 20
2004 13
2005 15
2006 18
2007 10
2008 6
2009 10
2010 10
2011 14
2012 11
2013 7
2014 4
2015 16
2016 15
2017 6
2018 8
2019 8
2020 8
2021 16
2022 8
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

376 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and Safety of Ultrahigh-Dose Methylcobalamin in Early-Stage Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial.
Oki R, Izumi Y, Fujita K, Miyamoto R, Nodera H, Sato Y, Sakaguchi S, Nokihara H, Kanai K, Tsunemi T, Hattori N, Hatanaka Y, Sonoo M, Atsuta N, Sobue G, Shimizu T, Shibuya K, Ikeda K, Kano O, Nishinaka K, Kojima Y, Oda M, Komai K, Kikuchi H, Kohara N, Urushitani M, Nakayama Y, Ito H, Nagai M, Nishiyama K, Kuzume D, Shimohama S, Shimohata T, Abe K, Ishihara T, Onodera O, Isose S, Araki N, Morita M, Noda K, Toda T, Maruyama H, Furuya H, Teramukai S, Kagimura T, Noma K, Yanagawa H, Kuwabara S, Kaji R; Japan Early-Stage Trial of Ultrahigh-Dose Methylcobalamin for ALS (JETALS) Collaborators. Oki R, et al. Among authors: shimohama s. JAMA Neurol. 2022 Jun 1;79(6):575-583. doi: 10.1001/jamaneurol.2022.0901. JAMA Neurol. 2022. PMID: 35532908 Free PMC article. Clinical Trial.
Dopamine receptors and Parkinson's disease.
Hisahara S, Shimohama S. Hisahara S, et al. Among authors: shimohama s. Int J Med Chem. 2011;2011:403039. doi: 10.1155/2011/403039. Epub 2011 Jun 13. Int J Med Chem. 2011. PMID: 25954517 Free PMC article. Review.
Disease model: Parkinson's disease.
Shimohama S, Sawada H, Kitamura Y, Taniguchi T. Shimohama S, et al. Trends Mol Med. 2003 Aug;9(8):360-5. doi: 10.1016/s1471-4914(03)00117-5. Trends Mol Med. 2003. PMID: 12928038 Review.
Roles of Nicotinic Acetylcholine Receptors in the Pathology and Treatment of Alzheimer’s and Parkinson’s Diseases.
Shimohama S, Kawamata J. Shimohama S, et al. 2018 Apr 4. In: Akaike A, Shimohama S, Misu Y, editors. Nicotinic Acetylcholine Receptor Signaling in Neuroprotection [Internet]. Singapore: Springer; 2018. Chapter 8. 2018 Apr 4. In: Akaike A, Shimohama S, Misu Y, editors. Nicotinic Acetylcholine Receptor Signaling in Neuroprotection [Internet]. Singapore: Springer; 2018. Chapter 8. PMID: 31314416 Free Books & Documents. Review.
The parkinsonian models: invertebrates to mammals.
Kitamura Y, Shimohama S, Akaike A, Taniguchi T. Kitamura Y, et al. Among authors: shimohama s. Jpn J Pharmacol. 2000 Nov;84(3):237-43. doi: 10.1254/jjp.84.237. Jpn J Pharmacol. 2000. PMID: 11138723 Free article. Review.
Mitochondrial abnormalities in Alzheimer's disease.
Hirai K, Aliev G, Nunomura A, Fujioka H, Russell RL, Atwood CS, Johnson AB, Kress Y, Vinters HV, Tabaton M, Shimohama S, Cash AD, Siedlak SL, Harris PL, Jones PK, Petersen RB, Perry G, Smith MA. Hirai K, et al. Among authors: shimohama s. J Neurosci. 2001 May 1;21(9):3017-23. doi: 10.1523/JNEUROSCI.21-09-03017.2001. J Neurosci. 2001. PMID: 11312286 Free PMC article.
376 results